A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD 123 X CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
MacroGenics, Inc.
Start Date
February 27, 2015
End Date
February 26, 2022
Administered By
Duke Cancer Institute
Awarded By
MacroGenics, Inc.
Start Date
February 27, 2015
End Date
February 26, 2022